Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This supports a moderately bullish consensus sentiment, with 1 Buy rating and 2 Hold calls. Copyright: dolgachov / 123RF Stock Photo Recent developments also back the bullish views on the stock, which has seen a significant amount of short interest lately. On April 17, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) made an appearance at the Needham Healthcare Conference, where CFO Ben Taylor shared details about the company's priorities for 2026. The company has entered a phase featuring regular data readouts and partnership milestones following the merger and restructuring completed last year. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) has delivered proof-of-concept data on its FAP molecule, with four clinical programs advancing. Over $500 million came from Sanofi, with $60 million from Roche MAP milestones. The Roche deal surpassed $210 mill
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6GlobeNewswire
- Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals May Be Losing Ground To Its Peers [Seeking Alpha]Seeking Alpha
- Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast [Yahoo! Finance]Yahoo! Finance
- A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form SCHEDULE
- 4/22/26 - Form 144
- RXRX's page on the SEC website